<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721342</url>
  </required_header>
  <id_info>
    <org_study_id>Remission Clinic</org_study_id>
    <nct_id>NCT02721342</nct_id>
  </id_info>
  <brief_title>Remission Clinic in Proteinuric Chronic Nephropathies</brief_title>
  <official_title>Remission Clinic: Computed Registry for the Ambulatory Follow up of Patients With Proteinuric Chronic Nephropathies Treated Based on a Standard Multipharmacological Model Aimed at Normalizing Proteinuria and Stabilizing the Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most chronic kidney diseases have a progressive evolution characterized by the gradual loss
      of glomerular filtration rate (GFR), electrolytic imbalance, reduced erythropoietin synthesis
      and activation of vitamin D. On many occasions, the progressive deterioration of renal
      function occurs, even when the etiologic factors responsible for the kidney disease are
      treated and/or eliminated as a result of an auto-sustained mechanism of inflammation and
      fibrosis. Moreover, chronic nephropathies are often associated with high blood pressure and
      increased urine protein excretion, being both risk factors of progression toward kidney
      failure. Many clinical studies have shown the efficacy of antihypertensive therapies,
      particularly the blockade of renin-angiotensin system, to lower the abnormal urinary protein
      excretion. Moreover, control of blood pressure and proteinuria slow the rate of renal
      function decline and in some cases even lead to recovery of kidney function avoiding the need
      for renal replacement therapies. The set of measures to achieve these results encompasses the
      term of &quot;renoprotective therapy&quot;. However these achievements have been obtained in the
      setting of clinical trials, and need confirmation in the daily clinical practice.

      To this purpose a standardized multidrug intervention model that aims at normalizing the
      excretion of urinary proteins and stabilizing the renal function has been developed for the
      outpatient-clinic and named &quot;Remission Clinic&quot;.

      The applicability of this protocol is aimed for all nephrology and diabetology centers.
      Through the use of a dedicated database computer network, it will be possible to share
      clinical, laboratory and treatment data, recorded for each patient enrolled in the Remission
      Clinic program. With this system, it will be possible to verify if the multidrug approach of
      the Remission Clinic will allow to improve the clinical course of chronic proteinuric
      nephropathy. All participants (centers) may access to the Remission Clinic website developed,
      updated and maintained by the Department of Bioengineering of the Mario Negri Institute,
      Bergamo, Italy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular Filtration Rate (GFR) estimated</measure>
    <time_frame>Changes from baseline at at least every 3 to 6 months for the duration of the study, an expected average of 10 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour proteinuria</measure>
    <time_frame>Changes from baseline at at least every 3 to 6 months for the duration of the study, an expected average of 10 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with fatal and non-fatal cardiovascular events</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected average of 10years.</time_frame>
    <description>Sudden death, myocardial infarction, unstable angina, stroke, transient ischemic attack, lower limb amputation, coronary, carotid or peripheral vessel revascularization.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Ramipril, Irbesartan and Atorvastin treatment</arm_group_label>
    <description>A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril, Irbesartan and Atorvastin</intervention_name>
    <arm_group_label>Ramipril, Irbesartan and Atorvastin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diabetic or non-diabetic chronic nephropathies, with no specific
        contraindications for treatment with ACEi or Sartans.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proteinuria &gt;0.5 g/24 hours or albuminuria &gt;200 g / min (or &gt;300 g/24 hours) for at
             least 2 consecutive evaluations regardless of treatment with ACEi and/or ARBs;

          -  Change in serum creatinine or creatinine clearance less than 30% in the last 3 months;

          -  No corticosteroids or immunosuppressants at the time of inclusion or given to patient
             in the last 6 months.

        Exclusion Criteria:

          -  Idiopathic membranous nephropathy;

          -  Focal segmental glomerulosclerosis;

          -  Minimal change glomerulopathy;

          -  Nephritic syndrome;

          -  Rapidly progressive renal failure (extracapillary glomerulonephritis in active phase);

          -  Any active renal disease that represents a possible indication to corticosteroids or
             immunosuppressive therapy;

          -  Nephropathies secondary to systemic disease susceptible to treatment with
             corticosteroids or immunosuppressive agents (Systemic Lupus Erythematosus, Vasculitis,
             Amyloidosis, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Piero Ruggenenti, MD</last_name>
    <phone>0039 035 45351</phone>
    <email>pruggenenti@asst-pg23.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò</name>
      <address>
        <city>Ranica</city>
        <state>Bergamo</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Daina, MD</last_name>
      <email>erica.daina@marionegri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni - Pierantoni - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Forlì</city>
        <state>Forli'</state>
        <zip>47011</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Mosconi, MD</last_name>
      <email>giovanni.mosconi@ausl.fo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl 6 Sanluri-P.O. Nostra Signora di Bonaria - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>San Gavino- Monreale</city>
        <state>Medio Campidano - VS</state>
        <zip>09037</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cristina Mereu, MD</last_name>
      <email>mariacristina.mereu@asl6sanluri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale C.G. Mazzoni Zona 13 ASUR Marche - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Ascoli Piceno</city>
        <zip>63100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Ragaiolo, MD</last_name>
      <email>m.ragaiolo@asl13.marche.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AORN Moscati - Avellino - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter De Simone, MD</last_name>
      <email>wadesimone@aosgmoscati.av.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Bergamo</city>
        <zip>20147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Ruggenenti, MD</last_name>
      <email>pruggenenti@hpg23.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII Bergamo - U.O. Diabetologia</name>
      <address>
        <city>Bergamo</city>
        <zip>20147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Trevisan, MD</last_name>
      <email>rtrevisan@hpg23.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Brotzu - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonello Pani, MD</last_name>
      <email>antonellopani@aob.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Campo di Marte - USL 2 - U.O. Nefrologia</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Rosati, MD</last_name>
      <email>arosati@usl2.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ARNAS Ospedale Civico Di Cristina Benfratelli - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Giammarresi, MD</last_name>
      <email>cgiammer@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Università degli Studi di Palermo - Dipartimento Malattie Cardiovascolari e Nefrourologiche - U.O. Tecniche Dialitiche</name>
      <address>
        <city>Palermo</city>
        <zip>90129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Li Vecchi, MD</last_name>
      <email>livecchi@unipa.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana - U.O. Nefrologia e Dialisi 2</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliano Barsotti, MD</last_name>
      <email>g.barsotti@med.unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo Fondazione Macchi - U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Maria Frattini, MD</last_name>
      <email>gianmaria.frattini@ospedale.varese.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic proteinuric nephropathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

